Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety registry of talimogene laherparepvec in previously treated trial participants
2015-003196-29Phase 4Unknown
- Sponsor
- Amgen
- Start
- Sep 2017
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of talimogene laherparepvec in cancer, sponsored by Amgen. Primary endpoint: Long-term safety. Status: unknown.
02
Drugs
talimogene laherparepvec
03
Conditions
cancer
Beyond the preview
Go deeper on 2015-003196-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003196-29.